CYP19A1 and breast carcinoma: In addition to successful trials as monotherapy in subsets of leukemia patients, HBI-8000 was tested in combination with exemestane [steroidal aromatase inhibitor (18)] in post-menopausal HR+ breast cancer patients (6).